These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 1647552)

  • 1. Antithrombotic and anticoagulant activity of depolymerized fragment of the glycosaminoglycan extracted from Stichopus japonicus Selenka.
    Suzuki N; Kitazato K; Takamatsu J; Saito H
    Thromb Haemost; 1991 Apr; 65(4):369-73. PubMed ID: 1647552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombin III-independent effect of depolymerized holothurian glycosaminoglycan (DHG) on acute thromboembolism in mice.
    Nagase H; Kitazato KT; Sasaki E; Hattori M; Kitazato K; Saito H
    Thromb Haemost; 1997 Feb; 77(2):399-402. PubMed ID: 9157603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged bleeding time induced by anticoagulant glycosaminoglycans in dogs is associated with the inhibition of thrombin-induced platelet aggregation.
    Kitazato K; Kitazato KT; Sasaki E; Minamiguchi K; Nagase H
    Thromb Res; 2003; 112(1-2):83-91. PubMed ID: 15013278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anticoagulant and hemorrhagic effects of DHG, a new depolymerized holothurian glycosaminoglycan, on experimental hemodialysis in dogs.
    Minamiguchi K; Kitazato KT; Sasaki E; Nagase H; Kitazato K
    Thromb Haemost; 1997 Jun; 77(6):1148-53. PubMed ID: 9241748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of depolymerized holothurian glycosaminoglycan (DHG) on tissue factor pathway inhibitor: in vitro and in vivo studies.
    Nagase H; Enjyoji K; Kamikubo Y; Kitazato KT; Kitazato K; Saito H; Kato H
    Thromb Haemost; 1997 Aug; 78(2):864-70. PubMed ID: 9268186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depolymerized holothurian glycosaminoglycan (DHG), a novel alternative anticoagulant for hemodialysis, is safe and effective in a dog renal failure model.
    Minamiguchi K; Kitazato KT; Nagase H; Sasaki E; Ohwada K; Kitazato K
    Kidney Int; 2003 Apr; 63(4):1548-55. PubMed ID: 12631372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DHG, a new depolymerized holothurian glycosaminoglycan, exerts an antithrombotic effect with less bleeding than unfractionated or low molecular weight heparin, in rats.
    Kitazato K; Kitazato KT; Nagase H; Minamiguchi K
    Thromb Res; 1996 Oct; 84(2):111-20. PubMed ID: 8897700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depolymerized holothurian glycosaminoglycan with novel anticoagulant actions: antithrombin III- and heparin cofactor II-independent inhibition of factor X activation by factor IXa-factor VIIIa complex and heparin cofactor II-dependent inhibition of thrombin.
    Nagase H; Enjyoji K; Minamiguchi K; Kitazato KT; Kitazato K; Saito H; Kato H
    Blood; 1995 Mar; 85(6):1527-34. PubMed ID: 7888673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased concentrations of heparinoids are required to inhibit thrombin generation in plasma from newborns and children compared to plasma from adults due to reduced thrombin potential.
    Chan AK; Berry LR; Monagle PT; Andrew M
    Thromb Haemost; 2002 Apr; 87(4):606-13. PubMed ID: 12008942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
    Wolzt M; Weltermann A; Nieszpaur-Los M; Schneider B; Fassolt A; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition.
    Momi S; Nasimi M; Colucci M; Nenci GG; Gresele P
    Haematologica; 2001 Mar; 86(3):297-302. PubMed ID: 11255277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin.
    Atkinson HM; Mewhort-Buist TA; Berry LR; Chan AK
    Thromb Haemost; 2009 Jul; 102(1):62-8. PubMed ID: 19572069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo.
    Eichinger S; Wolz M; Nieszpaur-Los M; Schneider B; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1994 Dec; 72(6):831-5. PubMed ID: 7740450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure and anticoagulant activity of fucosylated glycosaminoglycan degraded by deaminative cleavage.
    Zhao L; Lai S; Huang R; Wu M; Gao N; Xu L; Qin H; Peng W; Zhao J
    Carbohydr Polym; 2013 Nov; 98(2):1514-23. PubMed ID: 24053834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fucosylated chondroitin sulfate as a new oral antithrombotic agent.
    Fonseca RJ; Mourão PA
    Thromb Haemost; 2006 Dec; 96(6):822-9. PubMed ID: 17139379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An approach to assigning in vitro potency to unfractionated and low molecular weight heparins based on the inhibition of prothrombin activation and catalysis of thrombin inhibition.
    Ofosu FA; Smith LM; Anvari N; Blajchman MA
    Thromb Haemost; 1988 Oct; 60(2):193-8. PubMed ID: 2851191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
    Melo FR; Mourão PA
    Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralization of DHG, a new depolymerized holothurian glycosaminoglycan, by protamine sulfate and platelet factor 4.
    Sasaki E; Minamiguchi K; Kitazato KT; Nagase H; Kitazato K
    Haemostasis; 1997; 27(4):174-83. PubMed ID: 9483172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose response relationships of anticoagulant activities after subcutaneous administration of two low molecular weight heparins in healthy individuals.
    Hellstern P; Kiehl R; von Blohn G; Köhler M; Meierhenrich U; Wenzel E
    Thromb Haemost; 1986 Oct; 56(2):225-8. PubMed ID: 3810557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors.
    Calatzis A; Peetz D; Haas S; Spannagl M; Rudin K; Wilmer M
    Am J Clin Pathol; 2008 Sep; 130(3):446-54. PubMed ID: 18701419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.